ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 107,48
0,19%
Dow Jones
39 671,04
-0,51%
DAX
18 733,28
0,27%
Brent Oil
82,315
0,96%
Bitcoin
69 721,26
0,89%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Hoth Therapeutics Inc (HOTH)

  7. Hoth Therapeutics Inc (HOTH) Actualités

HOTH

Hoth Therapeutics (HOTH)

Hoth Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:HOTH
DateHeureSourceTitreSymboleSociété
14/05/202422h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HOTHHoth Therapeutics Inc
01/05/202414h00PR Newswire (US)Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024NASDAQ:HOTHHoth Therapeutics Inc
27/03/202419h00PR Newswire (US)Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross ProceedsNASDAQ:HOTHHoth Therapeutics Inc
27/03/202413h27PR Newswire (US)Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity TreatmentNASDAQ:HOTHHoth Therapeutics Inc
19/03/202413h21PR Newswire (US)Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZNASDAQ:HOTHHoth Therapeutics Inc
29/02/202414h38PR Newswire (US)Hoth Therapeutics Retains Venable LLP to Expand Its Patent PortfolioNASDAQ:HOTHHoth Therapeutics Inc
26/02/202414h11PR Newswire (US)Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting TherapeuticNASDAQ:HOTHHoth Therapeutics Inc
13/02/202417h45PR Newswire (US)Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024NASDAQ:HOTHHoth Therapeutics Inc
18/01/202414h20PR Newswire (US)Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill PatientsNASDAQ:HOTHHoth Therapeutics Inc
09/01/202421h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOTHHoth Therapeutics Inc
08/01/202423h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOTHHoth Therapeutics Inc
27/12/202314h21PR Newswire (US)Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of MiamiNASDAQ:HOTHHoth Therapeutics Inc
05/12/202314h33PR Newswire (US)Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling StudiesNASDAQ:HOTHHoth Therapeutics Inc
14/11/202314h37PR Newswire (US)Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KITNASDAQ:HOTHHoth Therapeutics Inc
10/11/202314h00PR Newswire (US)Hoth Therapeutics to Present at NobleCon's 19th Annual Emerging Growth Investor Conference, December 3-5, 2023NASDAQ:HOTHHoth Therapeutics Inc
05/10/202316h03PR Newswire (US)Hoth Therapeutics Announces Merveille.ai Artificial intelligence Initiative for Drug DiscoveryNASDAQ:HOTHHoth Therapeutics Inc
02/10/202314h33PR Newswire (US)FDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT, Treatment for Cancer PatientsNASDAQ:HOTHHoth Therapeutics Inc
15/09/202320h38PR Newswire (US)Hoth Therapeutics Announces Closing of $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesNASDAQ:HOTHHoth Therapeutics Inc
14/09/202323h24Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:HOTHHoth Therapeutics Inc
13/09/202319h43PR Newswire (US)Hoth Therapeutics Announces $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesNASDAQ:HOTHHoth Therapeutics Inc
13/09/202314h16PR Newswire (US)Hoth Therapeutics Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid LeukemiaNASDAQ:HOTHHoth Therapeutics Inc
11/09/202316h04PR Newswire (US)Hoth Therapeutics Announces FDA Accepts Pre-Investigational New Drug (Pre-IND) Submission for HT-KIT, Treatment for Cancer PatientsNASDAQ:HOTHHoth Therapeutics Inc
06/09/202314h12PR Newswire (US)Hoth Therapeutics Announces Positive Final Results from 14-day Phase 1b Clinical Trial of BioLexaNASDAQ:HOTHHoth Therapeutics Inc
21/08/202323h00Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:HOTHHoth Therapeutics Inc
09/08/202314h13PR Newswire (US)Hoth Therapeutics Announces Positive Preclinical End Point Results of HT-ALZ Treatment for Alzheimer's DiseaseNASDAQ:HOTHHoth Therapeutics Inc
25/07/202314h12PR Newswire (US)Hoth Therapeutics Announces Major Milestone of First Patient Dosed in Phase 2a Clinical TrialNASDAQ:HOTHHoth Therapeutics Inc
19/07/202314h02PR Newswire (US)Hoth Therapeutics Receives Protocol Approval for HT-001 Cancer TherapeuticNASDAQ:HOTHHoth Therapeutics Inc
27/06/202322h22Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:HOTHHoth Therapeutics Inc
27/06/202322h21Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:HOTHHoth Therapeutics Inc
14/06/202314h12PR Newswire (US)Hoth Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial of HT-001 at Second Clinical SiteNASDAQ:HOTHHoth Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:HOTH

Dernières Valeurs Consultées

BIT
I07343
INTESA SANPAOLO
CRTO
KEEPUSDT
KEEP Token
CSE
QNI
Quebec Nickel
BIT
P1YC18
NLBNPIT1YC18 20351221 12...
NYSE
BBT-D
BB and T
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés